According to an article recently released by Bloomberg.com, results from pandemic influenza vaccine trails coming out of Australia and the United States found the receipt of a single, unadjuvanted pandemic influenza vaccine to be effective (conferring protective antibody response). Australian-based manufacturing company CLS Ltd. reported that more than 95% of study patients had protective levels of antibodies 3 weeks after vaccination, while a U.S. study found a single vaccination to be effective within 8-10 days. No serious side effects were reported, though trails are too small to detect rare conditions. According to U.S. officials, potential adverse vaccine reactions will be closely monitored once vaccination campaigns begin.
An effective single dose of pan flu vaccine has implications for developing countries, as these findings may double anticipated stockpiles of vaccine and render more vaccine available in developing countries.
CSL Ltd. said it plans to donate its vaccine to developing nations in Asia and the South Pacific. The company is also discussing a pilot program with the World Health Organization, for which an initial donation of 100,000 vaccine doses would be made. Nancy Cox, director of the influenza division at the U.S. Centers for Disease Control and Prevention, said the U.S. is in “very active discussions” about donating some of its supply to countries in need.
View the entire Bloomberg article at:
http://www.bloomberg.com/apps/news?pid=20601124&sid=asYlPo7IOFqw
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment